Abano sees opportunities in Australia and NZ


"Consolidation activity in the dental sector in Australia is ongoing. Abano has received various expressions of interest, which may offer strategic opportunities and value to shareholders," it said in a statement.

The group said that it had "paused acquisitions in Australia", given current Australian acquisition multiples and trading conditions. It said that capital will be invested in New Zealand acquisitions to grow the existing Lumino network.

At the same time the group confirmed guidance for the year. Full year results to the end of May should see EBITDA of NZ$32.7m (US$22m) with NPAT of NZ$10.1m.

Abano shares slumped 32% at the end of March after it downgraded its earnings outlook, but have recovered since then. They closed the day up 17.85% at NZ$4.16.



Do you have some news or a press release that you’d like to share with the medical travel industry?

Publish for FREE on IMTJ.


Related News

Dubai medical tourism analysis

07 November, 2019

337,011 ‘international patients’ to Dubai in 2018

Jamaica’s medical travel inertia

24 October, 2019

Healthcare accreditation, investment and Jamaican government support is lacking

Costa Rica promotes stem cell treatment

23 October, 2019

Costa Rica looks to be stem cell treatment destination

UAE opens up for investment

15 October, 2019

UAE healthcare to attract foreign ownership

Kazakhstan outbound medical tourism risk

10 October, 2019

Compulsory health insurance from 2020 will cut medical travel